Antiplatelet therapy is a mainstay in the management of coronary artery disease. Indeed, optimal and rapid inhibition of platelet function is a key therapeutic goal in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. Currently, dual antiplatelet treatment with aspirin and clopidogrel is the gold standard care in patients with acute coronary syndromes or receiving coronary stents without prohibitive bleeding risk. However, recent data show that the efficacy of clopidogrel is hampered by its slow and variable platelet inhibition, with ensuing increased risk of ischemic events, including death, myocardial infarction and stent thrombosis. Novel agents such as prasugrel and ticagrelor have been developed to clopidogrel limits and thus improve cardiovascular outcomes. This article presents a comprehensive overview of the benefits and limitations of current and shortly available antiplatelet agents, providing detailed arguments in favor and against prasugrel and ticagrelor.
Introduction
Dual antiplatelet theraphy in patients with acute coronary artery disease Acute coronary syndromes (ACS) are the leading cause of mortality and hospital admission worldwide. In the last years, the great improvement of ACS treatment has been supported on one hand by the development of interventional devices and on the other hand by the major advances in antiplatelet therapy, including increased adherence. [1] [2] [3] [4] [5] The main goal of optimal antiplatelet therapy in the setting of ACS is to minimize early and long term thrombotic adverse events, especially fatal or non-fatal myocardial infarction and stent thrombosis, as well as to reduce bleeding complications. 6 Although aspirin still remains the cornerstone of antiplatelet therapy in patient undergoing coronary revascularization and then for lifelong care, 4, [7] [8] dual antiplatelet therapy with aspirin and a thienopyridine showed better clinical outcomes compared to aspirin alone in patients with ACS or aspirin plus warfarin in patients with ACS or receiving a coronary stent. [9] [10] [11] [12] The better safety and efficacy profile, including clinical outcomes after percutaneous coronary intervention (PCI), of clopidogrel (Plavix, Bristol Myers Squibb-Sanofi Aventis), a second generation thienopyridine, lead the large application in clinical practice of this drug over ticlopidine (Table 1) . [11] [12] [13] [14] [15] [16] [17] The efficacy of clopidogrel added to aspirin in patients with ACS was indeed largely established in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial. [11] [12] 18 This study randomized 12,562 patients to receive clopidogrel (loading dose of 300 mg and maintaining dose of 75 mg daily) or placebo in addition to aspirin. Clopidogrel plus aspirin lowered a composite of death, myocardial infarction, and stroke from 4.8% to 3.9% (P=0.007) at 30 days and this benefit was durable through 12 months follow-up yielding a 20% relative reduction in risk (11.4% to 9.3%; P<0.001) regardless of aspirin dose. However, there was an increase in major bleeding events (3.7% vs 2.7%; P=0.001) with dual antiplatelet therapy. Despite the intense antiplatelet effect provided by aspirin plus clopidogrel, as much as 5.2% of such patients had a myocardial infarction, and 5.1% had died from cardiovascular causes at 1-year follow-up, suggesting that further improvements in ACS management could be made.
In the prospectively designed PCI-CURE substudy a strategy of clopidogrel pretreatment followed by long-term therapy was associated with a lower rate of cardiovascular death, myocardial infarction, or any revascularization (P=0.03), and of cardiovascular death or myocardial infarction (P=0.047) compared to placebo. 12 Overall (including events before and after PCI), there was a 31% reduction in the risk of cardiovascular death or myocardial infarction (P=0.002). There was also less use of glycoprotein IIb/IIIa inhibitors in the clopidogrel group (P=0.001). Intriguingly, at followup there was no significant difference in major bleeding between the groups (P=0.64). 12 
Drawbacks of standard dose clopidogrel
The persistence of enhanced platelet reactivity, despite a 300 to 600 mg loading dose or 75 to 150 mg maintenance dose of clopidogrel, is a clinically relevant entity and is due to a complex interplay between environmental and genetic factors. 19 It is estimated that 30% of European, 40% of African, and more than 50% of Asian patients exhibit a diminished response to clopidogrel.
In a genetic substudy of the randomized Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38), the cytochrome CYP2C19 loss-of-function allele was significantly associated with risk of the primary endpoint of cardiovascular death, myocardial infarction, or stroke (P=0.0064). 20 This result was confirmed by a meta analysis from 9 studies evaluating CYP2C19 genotype in patients treated with clopidogrel. Specifically, among 9685 subjects (91.3% undergoing PCI and 54.5% with ACS), the composite end point of cardiovascular death, myocardial infarction, or stroke was significantly increased in both heterozygote and homozygote for reduced-function alleles (hazard ratio=1.55 [95% confidence interval 1.11-2.17], P=0.01, and hazard ratio=1.76 [1.24-2.50], P=0.002, respectively). Similarly, there was an increased risk of stent thrombosis in both groups with the hazard alleles. 21 Genetic variations affecting the cytochrome activity have been also correlated to pharmacologic interaction between clopidogrel and others drugs that fill the same enzymatic pathway. Particularly, several trials investigated the outcomes of patients concomitantly treated with clopidogrel and omeprazole, but results are equivocal: Ho and colleagues 22 demonstrated that concomitant use of clopidogrel and PPI after hospital discharge for ACS was associated with an increased risk of adverse outcomes than use of clopidogrel alone; on the other N o n -c o m m e r c i a l u s e o n l y side, in the COGENT trial 23 there was no apparent cardiovascular interaction between clopidogrel and omeprazole, and clinical results did not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.
To identify the poor response to thienopyridine, several methods was developed in the clinical setting. Actually, Verify Now and Vasodilator Stimulated Phosphoprotein (VASP) are the most used test. Verify Now is a turbidimetric test which measures agonistinduced aggregation as an increase in light transmittance, and grants high clinical sensitivity and specificity. The cut-off between poor responders and responders in clinical trials ranges from 235 to 240. 24 VASP is a flow cytometric assay which calculated the platelet reactivity index (PRI) from the median fluorescence intensity (MFI) of samples incubated with PGE1 or PGE1 and ADP. Non-response to clopidogrel was defined as PRI VASP > 50% 25 Although both Verify Now and VASP has been associated with clinical prognosis after PCI, [24] [25] [26] [27] [28] recent study by Cuisset et al. demonstrated a poor agreement between different platelet assays and suggested that identification of clopidogrel non responders is test-dependent. 29 Recently, modified release clopidogrel formulation is developed using its pharmaceutically acceptable salts. In animal model, the new clopidogrel napadisilate salt shows better stability and bioequivalence to the standard formulation suggesting a promising candidate for clinical setting. 30 Risk-benefit balance of high-dose clopidogrel Dual antiplatelet therapy by 600 mg loading dose of clopidogrel provides faster and greater platelet inhibition in patients with ACS, which could translate into reduced adverse cardiac events. [31] [32] [33] A meta-analysis from 10 studies by Lotrionte et al demonstrated that a high loading dose proved significantly superior to a standard loading dose in preventing cardiac death or nonfatal myocardial infarction (P=0.02), without any statistically significant increase in major or minor bleedings. 2 Sensitivity analysis restricted to randomized trials confirmed such superiority of a high loading dose regimen (P=0.003). Accordingly, meta-regression disclosed a significant interaction between event rate and the benefits of high loading doses (P=0.005), suggesting that the greater the underlying risk, the greater the favorable impact of a high loading dose. 2 These findings are in contrast with the largest randomized study on the topics, the Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-Seventh Organization to Assess Strategies in Ischemic Syndromes (CURRENT OASIS 7) trial, in which 25,086 patients with ACS were randomized to 600 mg clopidogrel loading dose, followed by 150 mg daily for a week and then 75 daily versus a 300 mg loading dose, followed by 75 mg daily maintenance therapy (Table 1) . 34 The primary end-point of cardiovascular death, myocardial infarction, or stroke at 30 days, was not significantly different in the two group s (4.2% in patients in the high dose group versus 4.4% in patients in the standard dose group; hazard ratio=0.95 [0.84-1.07]). However, among patients managed with PCI within 24 hours (approximately two thirds of the study patients), high dose clopidogrel yielded a statistically significant 15% reduction in the composite of cardiovascular, death, myocardial infarction, or stroke (3.9% vs 4.5%; hazard ratio=0.85 [0.74-0.99]) that was driven mainly by significantly lower rates of myocardial infarction in the high dose clopidogrel group (2.0% vs 2.6%, HR 0.78, 95% CI: 0.64-0.95). There was also a significant 42% reduction in the risk of the key secondary endpoint of definite stent thrombosis in the high dose clopidogrel group (0.7% vs 1.2%; hazard ratio=0.58 [0.42-0.79]). However, reduction in the rates of ischemic endpoints was offset by higher rates of major bleeding with the higher clopidogrel dose both in the entire study population (2.5% vs 2.0%; hazard ratio=1.25 [1.05-1.47]) and in the PCI population (1.6% vs 1.1%; hazard ratio=1.44 [1.1-1.86]). 34 Recently, the GRAVITAS trial investigated in 35 The impact of further increasing the loading dose of clopidogrel to 900 mg has been evaluated recently but with inconclusive results. 36 
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Risk-benefit balance of prsugrel
Prasugrel is a third generation thienopyridine that exerts its antiplatelet effect binding irreversibly to the P2Y12 ADP receptor by an active metabolite (Table 1) . [37] [38] [39] Treatment with prasugrel results in faster and greater platelet inhibition than standard or high-dose of clopidogrel and a lower rate of non-responders. [40] [41] [42] [43] The Joint Utilization Of Medications To Block Platelets Optimally (JUMBO)-TIMI 26 trial was the first dose-finding study (phase II) focusing on this molecule in patients undergoing elective or urgent PCI. (41) Specifically, subjects were randomized to low dose (40 mg loading dose followed by 7.5 mg daily), intermediate dose (60 mg loading dose followed by 10 mg daily), or high dose (60 mg loading dose followed by 15 mg daily) of prasugrel or the standard dose of clopidogrel (300 mg loading dose followed by 75 mg daily). Treatment with prasugrel showed equivalent bleeding risk to clopidogrel (1.7% vs 1.2%; hazard ratio=1.42 [0. .0]), although more minimal bleeding was reported in the high dose prasugrel group compared with other prasugrel regimens and the clopidogrel group. There was a numerically lower incidence of major adverse cardiac events in the overall prasugrel group (7.2%) compared with the clopidogrel group (9.4%; P=0.26; hazard ratio=0.76 [0.46-1.24]), primarily driven by a reduction in myocardial infarction and urgent reintervention.
In the TRITON-TIMI 38 study, 13,608 moderate-to high-risk ACS patients undergoing PCI were randomized to prasugrel (60 mg loading dose, 10 mg daily maintenance dose) or clopidogrel (300 mg loading dose, 75 mg daily maintenance dose) ( Table 2) . 44 At 15 months, prasugrel proved more effective in reducing the risk of cardiovascular death, myocardial infarction, and stroke in comparison to clopidogrel (9.9% vs 12.1%, P<0.001). The difference between the treatment groups with regard to the rate of the this end-point was largely related to a significant reduction in myocardial infarction in the prasugrel group (7.4% vs 9.7%, P<0.001). The TRITON-TIMI 38 investigators also found significant reductions in the prasugrel group in the rates of urgent targetvessel revascularization (3.7% vs 2.5%, P<0.001), and stent thrombosis (2.4% vs 1.1%, P<0.001). However, the more potent antiplatelet effect of prasugrel was associated with a significant increase of TIMI major bleeding (2.5% vs 1.7%, P=0.03), with the excess risk mainly due to coronary artery bypass grafting (CABG)-related major bleeding (0.4% vs 0.1%, P=0.001). The balance of safety and efficacy favored clopidogrel over prasugrel especially in the elderly patients and in those weighing <60 kg or with previous ischemic attack. 44 A much greater benefit of prasugrel therapy was showed in the subgroup analysis of STEMI patients in whom this drug reduced by 21% the combined end-point of cardiovascular death, myocardial infarction, or urgent target vessel revascularization compared with clopidogrel without increasing the rate of major bleeding complication. 45 Similarly beneficial results were found among diabetics enrolled in the TRITON-TIMI 38 trial, as platelet inhibition with prasugrel resulted in a greater benefit in reducing ischemic events and improving outcomes in those with diabetes mellitus, concomitantly with no increase in bleeding risk. 46 A post-hoc analysis was also performed in 12,844 patients undergoing PCI and stenting. The clinical benefit of prasugrel was similar with all stent types. Indeed, stent thrombosis was markedly and significantly reduced by prasugrel compared with clopidogrel in the overall cohort (2.0% vs 0.8%, P<0.0001), as well as in the stent subset. The greatest absolute benefits were seen in patients at higher risk for stent thrombosis, such as those with longer stents, bifurcation lesions, impaired kidney function, and diabetes. Similar benefits of prasugrel were also seen in patients who received the study drug before PCI (0.8% vs 2.2%, hazard ratio=0.37, P=0.002) or after coronary angioplasty was started (1.2% vs 2.4%, hazard ratio=0.51, P<0.0001, P for interaction =0.39). 47 Nonetheless, in a major recent twist, Bonello et al have challenged the uniformity of effect of prasugrel, in as much as been demonstrated for clopidogrel and aspirin. [48] [49] Specifically, they showed that among 301 patients with ACS treated with prasugrel, 25% had high on-treatment platelet reactivity. Moreover, patients with high on-treatment platelet reactivity had a significantly increased risk of major adverse cardiac events, but not an increased risk of bleeding.
Randomized trials demonstrated that the clinical benefits of plasugrel are limited in a population of age >75 years, previous TIA and/or stroke and a body weight less than 60 kg. In this subset of patients, FDA contraindicates the use of plasugrel.
Risk-benefit balance of ticagrelor
Ticagrelor is the first reversible oral P2Y12 ADP receptor antagonist. Clinical pharmacology studies suggested an early and greater inhibition of platelet aggregation (2 hours to peak platelet inhibition) without a proportional increase in bleeding risk in comparison to clopidogrel (Table 1) . [50] [51] The rapid reversal effect after discontinuation of the drug (within 12 hours) in fact minimizes the bleeding complications even in patients requiring surgical interventions. In the Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non-ST segment Elevation myocardial infarction (DISPERSE 2) trial, treatment with ticagrelor was associated with a numerically lower incidence of major bleeding among patients undergoing CABG 1-5 days after the drug stopping with a similar profile of safety and efficacy to clopidogrel. 52 The efficacy and safety of ticagrelor in the setting of ACS have been further evaluated in the phase III Platelet Inhibition and Patient Outcomes (PLATO) trial (Table 2) . 53 This study randomized approximately 18,000 patients, including those with ST-elevation as well as non-ST-elevation myocardial infarction, to 180 mg loading dose, 90 mg twice daily thereafter of ticagrelor versus 300-600 mg loading dose, 75 mg daily thereafter of clopidogrel. All patients received aspirin (75-100 mg daily). During the 12-month follow-up period, the risk of death from vascular causes, myocardial infarction, or stroke was significantly reduced by ticagrelor (9.8% vs 11.7%, P<0.001), an effect stemming from consistent reductions in the risk of death from all causes (4.5% vs 5.9%, P<0.001), death from vascular causes (4.0% vs 5.1%, P=0.001), and myocardial infarction (5.8% vs 6.9%,P=0.005), including stent thrombosis (1.3% vs 1.9%, P=0.009). Stroke occurred with similar frequency in the ticagrelor and clopidogrel groups (1.5% vs 1.3%, P=0.2), similarly to CABG-related major bleeding (4.8% vs 5.2%, P=0.3) and all TIMI major bleedings (7.1% vs 6.9%, P=0.7). However, non-CABG related bleeding still occurred more frequently in the ticagrelor group (2.8% vs 2.2%, P=0.030) with a unfavorable trend especially for the intracranial bleeding (0.3% vs 0.2%, P=0.06). Ticagrelor patients had also higher incidences of dyspnea(13.8% vs 7.8%, P=0.001) and ventricular pauses (5.8% vs 3.6%, P=0.01)compared to clopidogrel. 53 A subgroup analysis of the PLATO trial 54 showed a significant interaction between treatment and region (P=0.045), with less effect of ticagrelor in North America than in the rest of the world, probably due to higher (>300 mg) daily aspirin maintenance dose than in other regions. Authors observed that the lowest risk of cardiovascular death, myocardial infarction, or stroke with ticagrelor compared with clopidogrel is associated with a low maintenance dose of aspirin. The antiplatelet effect of ticagrelor in patients who are nonresponsive to Clopidogrel was also investigated in the Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies (RESPOND) study. 55 The non-responsiveness to clopidogrel was defined as a <10% absolute change in 20 µmol/L ADP-induced platelet aggregation between the baseline value and at 6-8 h after the 300 mg clopidogrel loading dose. In a two-way crossover design, nonresponders and responders were randomly assigned to receive clopidogrel (600 mg loading dose then 75 mg daily) or ticagrelor (180 mg loading dose then 90 mg twice daily) for 14 days. The authors demonstrated that: i) ticagrelor was associated with greater platelet inhibition compared with clopidogrel treatment in both clopidogrel responders and nonresponders; ii) the antiplatelet effect of ticagrelor was largely not influenced by clopidogrel response status, and ticagrelor consistently overcame clopidogrel nonresponsiveness; iii) during switching of therapies, ticagrelor produced a rapid enhancement in platelet inhibition in both clopidogrel responders and nonresponders, whereas changing to clopidogrel therapy was associated with a reduction in platelet inhibition; and iv) ticagrelor was extremely effective in reducing the prevalence of high platelet reactivity without increases the ischemic risk. 55 
Other antipiastinic drugs
Cangrelor is an intravenous nonthienopyridine adenosine triphosphate analogue that blocks the adenosine diphosphate receptor P2Y12 (Table 1) . It was compared to high dose (600 mg) loading clopidogrel in two large, phase 3, randomized clinical trials, in which cangrelor was administered before PCI 56 or after PCI. 57 In both trials the primary efficacy end point was a composite of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours. In the CHAM-PION PCI trial 56 were enrolled 8877 patients. In the CHAMPION PLATFORM trial 57 were enrolled 5362 patients. Cangrelor, administered both before and after PCI, was not superior to clopidogrel in reducing the primary end point.
Elinogrel is a P2Y12 blocker available in both intravenous and oral formulations ( Table  1) . INNOVATE-PCI 58 is a phase 2 trial. The preliminary results have been presented at the ESC 2010 symposium. In the INNOVATE-PCI 616 patients were assigned pre-PCI to clopidogrel 300 or 600 mg followed by 75 mg/day, or to elinogrel 80 mg IV bolus followed by 50, or 150 mg oral elinogrel twice daily. Safety and efficacy endpoints were similar in the elinogrel low and high dose and clopidogrel group. Further phase 3 studies are actually scheduled to evaluate the impact of elinogrel on ACS patients.
Direct and indirect comparison
The main studies with employing high dose clopidogrel, prasugrel and ticagrelor in patients with ACS are summarized in Table 1 . Although recent data suggest a superior antithrombotic efficacy of both prasugrel and ticagrelor in combination to aspirin instead of clopidogrel, a direct comparison between these drugs has not been performed yet, and is unlikely to be completed in the foreseeable future.
An indirect head-to-head comparison of prasugrel versus ticagrelor has nonetheless been recently performed by Biondi-Zoccai and colleagues, within the context of a adjusted metaanalysis. 59 The conclusion of this paper was that there were no significant difference in the risk of death (odds ratio=1. 22 60 Conversely, Serebruany compared the findings of TRITON-TIMI 38 and PLATO trials, suggesting that ticagrelor, despite an unfavorable immediate safety profile, is clearly superior to prasugrel for chronic preventive use because of reductions inabsolute mortality, prevention of recurrent myocardial infarction, benefit on vascular outcomes which grows over time benefit, fewer bleeding fatalities, potentially fewer CABG-related bleedings, and lack of cancer risks. He concluded that ticagrelor will not substitute completely prasugrel, but in appropriate patients it will be a promising treatment. 61 
Conclusions
The choice of antiplatelet drug agent(s) should be based on the individual patient characteristics and the management strategy of ACS (Figure 2 ). Double loading dose and higher maintenance dose of clopidogrel may be considered for high risk patients. In those who experience adverse events despite ongoing clopidogrel therapy, alternative drugs may be envisioned. Prasugrel may indeed be preferred those at higher risk of thrombotic events, such as diabetics patients and/or those with diffuse coronary stenting. By its rapid onset of action, it may be preferred in patients Article Review requiring urgent intervention and particularly in the ST-elevation myocardial infarction setting. This agent should be however avoided in those at higher risk of bleeding (underweight, old age, and prior cerebrovascular events), when clopidogrel or ticagrelor provide a more favorable risk-benefit balance.
Ticagrelor may be also preferred in patients in whom CABG is a viable option. Patients with lung disease, advanced renal failure, and rhythm disorders should however avoid ticagrelor. Finally, in selected situations of complex coronary interventions and need for rapid onset of ADP receptors inhibition but still concerns over long-term bleeding risk, a combination of short-term use of prasugrel (60 mg load and 10 mg maintenance for 3-7 days) followed by clopidogrel 75 mg maintenance dose up to 1 year could be recommended.
All these approaches could also benefit by ad hoc measurement of platelet function and genotyping for key alleles, even if the cost-benefit implications of such personalized medicine approaches remain unclear. 62 
